Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

3.990 -0.180 (-4.32%)
Streaming Delayed Price Updated: 11:32 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
What's Going On With UroGen Pharma Stock Wednesday?
UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution. 
Via Benzinga
UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled
The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13. 
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
Via Benzinga
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
The company is working on a treatment for non-muscle invasive bladder cancer. 
Via Investor's Business Daily
Top stock movements in today's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer. 
Via Benzinga
Earnings Outlook For UroGen Pharma
Via Benzinga
Recap: UroGen Pharma Q3 Earnings
Via Benzinga
Preview: UroGen Pharma's Earnings
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Earnings Scheduled For March 10, 2025
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
Via Benzinga
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of... 
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil. 
Via Benzinga
Topics ETFs
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.